<DOC>
	<DOCNO>NCT02024334</DOCNO>
	<brief_summary>A randomized double blind clinical trial ass efficacy leflunomide treatment refractory juvenile idiopathic arthritis . Patients randomly divide two group . In group 1 leflunomide group 2 placebo add conventional treatment three month . therapeutic response evaluate ACRpedi ( American College Rheumatology Pediatric ) score every 4 week .</brief_summary>
	<brief_title>Efficacy Study Leflunomide Treat Juvenile Idiopathic Arthritis</brief_title>
	<detailed_description>30 Patients ( 2-19 ) randomly divide two group . In group 1 leflunomide add conventional treatment , 5-20 mg daily base weight . In group 2 placebo prescribe leflunomide . The course treatment 3 month . Every 4 week ACRped 30 , 50 , 70 determine evaluate therapeutic response . Side effect treatment assess physical examination lab test every 4 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Juvenile</mesh_term>
	<mesh_term>Leflunomide</mesh_term>
	<criteria>JIA base ACR criterion age 2 19 polyarticular , oligoarticular ( &gt; = 3 active joint ) extend oligoarticular subtypes resistance conventional treatment pregnancy malignancy severe active infection rheumatic disease overlap ALT ( Alanine transaminase ) bilirubin &gt; 3 fold IVIG ( Intravenous immunoglobulin ) treatment last 2 week biologic agent last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>19 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>JIA</keyword>
	<keyword>LEFLUNOMIDE</keyword>
	<keyword>EFFICACY</keyword>
</DOC>